The challenge of predicting drug toxicity in silico

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 3, 2006, Pages 195-208

  Vedani, Angelo ^a,b   Dobler, Max ^a   Lill, Markus A ^a,b  

^a Biographics Laboratory 3R   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANDROGEN RECEPTOR; ANTIANDROGEN; AROMATIC HYDROCARBON RECEPTOR; BETA CARBOLINE; BIPHENYL DERIVATIVE; CELL NUCLEUS RECEPTOR; CYPROTERONE; CYTOCHROME P450 3A4; DIBENZODIOXIN DERIVATIVE; DIBENZOFURAN; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANABENZ; HARMALINE; HARMALOL; HARMOL; IDAZOXAN; MEPROBAMATE; POLYCYCLIC AROMATIC HYDROCARBON; THYROID HORMONE; XENOBIOTIC AGENT;

ALGORITHM; ANISOTROPY; BINDING AFFINITY; BINDING SITE; COMPUTER MODEL; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DEPRESSION; DRUG CONFORMATION; DRUG EFFECT; ENDOCRINE DISEASE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; HYPERLIPIDEMIA; HYPOTHYROIDISM; IC 50; IMMUNOTOXICITY; MOLECULAR DYNAMICS; MONTE CARLO METHOD; NONHUMAN; OBESITY; OSTEOPOROSIS; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCTIVE TOXICITY; SHORT SURVEY; SKIN TOXICITY; SOLVATION; TOXICITY TESTING; TUMOR PROMOTION;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; SOFTWARE;

ANIMALIA;

EID: 33748286994     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_471.x     Document Type: Short Survey

References (87)

1. Anderson, M. E.: Toxicokinetic modeling and its application in chemical risk assessment. Toxicol. Lett. 2003, 18, 9-27.
2. Borman, S.: A.F.A. Cros, Ph.D. Thesis, University of Strasbourg, 1863 cited from "New QSAR techniques eyed for environmental assessments". Chem. & Eng. News 1990, 19, 20-23.
3. Bugrim, A., T. Nikolskaya & Y. Nikolski: Early prediction of drug metabolism and toxicity: Systems biology approach and modeling. Drug Discovery Today 2004, 9, 127-135.
4. Carlsen, E., A. Giwercman, N. Keiding & N. E. Skakkebæk: Evidence for decreasing quality of semen during past 50 years. Brit. Med. J. 1992, 305, 609-613.
5. Colborn, T.: Environmental estrogens: Health implications for humans and wildlife. Environ. Health Perspect. 1995, 103, 135-136.
6. Colborn, T., F. S. von Saal & A. M. Soto: Developmental effects of endocrine-disrupting chemicals in wildlife and humans (see comments). Environ. Health Perspect. 1993, 101, 378-384.
7. Cramer, C. J. & D. G. Truhlar: AM1-SM2 and PM3-SM3 parametrized SCF solvation models for free energies in aqueous solution. J. Comp.-Aided Molec. Design 1992, 6, 629-666.
8. Cramer, R. D., D. E. Patterson & J. D. Bunce: Comparative molecular fields analysis (CoMFA). I. Effect of shape on binding of steroids to carrier proteins. J. Amer. Chem. Soc. 1988, 110, 5959-5967.
9. Cramer, R. D. & M. Milne: The lattice model: a general paradigm for shape-related structure-activity correlations. Abstracts of papers of the Am. Chem. Soc. Meeting, April 1979, COMP 44.
10. Denomme, M. A., K. Homonko, T. Fujita, T. Sawyer & S. Safe: Substituted polychlorinated dibenzofuran receptor-binding af-finities and hydrocarbon hydroxylase induction potenties - A QSAR analysis. Chem.-Biol.Interactions 1986, 57, 175-187.
11. Denomme, M. A., K. Homonko, T. Fujita, T. Sawyer & S. Safe: Effects of substituents on the cytosolic receptor-binding avidities and aryl hydrocarbon hydroxylase induction potencies of 7-substituted 2,3-dichlorodibenzo-p-dioxins. Mol. Pharmacol. 1985, 27, 656-661.
12. Dibb, S.: Swimming in a sea of estrogens. The Ecologist 1995, 25, 27-31.
13. Dobler, M., M. A. Lill & A. Vedani: From crystal structures and their analysis to the in silico prediction of toxic phenomena. Helv. Chim. Acta 2003, 86, 1554-1568.
14. Ekins, S., B. J. Crumb, R. D. Sarazan, J. H. Wikel & S. A. Wrighton: Three-dimensional structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Therap. 2002, 301, 427-434.
15. Ekins, S., G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel & S. A. Wrighton: Three- and four-dimensional quantitative structure-activity relationship analyses of cytochrome P450 3A4 inhibitors. J. Pharmacol. Exp. Therap. 1999, 290, 429-438.
16. Feldman, D. & A. Krishnan: Estrogens in unexpected places: Possible implications for researchers and consumers. Environ. Health Perspect. 1995, 103, 129-133.
17. Fischer, B.: Receptor-mediated effects of chlorinated hydrocarbons. Andrologia 2000, 32, 279- 283.
18. Free, S. M. & J. W. Wilson: A mathematical contribution to structure-activity studies. J. Med. Chem. 1964, 7, 395-399.
19. Gao H., J. A. Katzenellenbogen, R. Garg & C. Hansch: Comparative QSAR analysis of estrogen receptor ligands. Chem. Rev. 1999, 99, 723-744.
20. Guillette, L. J., D. A. Crain A. A. Rooney & D. B. Pickford: Organization versus activation: the role of endocrine disrupting contaminants EDCs during embryonic development in wildlife. Environ. Health Perspect. 1995, 103, 157-164.
21. Gustaffson, J. A.: Receptor-mediated toxicity. Toxicol. Lett. 1995, 135, 465-470.
22. Hammet, L. P.: Reaction rates and indicator acidities. Chem. Rev. 1935, 17, 67-79.
23. Hampson, A. J. & M. Grimaldi: 12-hydroxyeicosatetrenoate (12-HETE) attenuates AMPA receptor-mediated neurotoxicity: Evidence for a G-protein coupled HETE receptor. J. Neurosci. 2002, 22, 257-264.
24. Hansch, C. & T. Fujita: ρ-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Amer. Chem. Soc. 1964, 86, 1616-1626.
25. Hansch, C. & J. M. Clayton: Lipophilic character and biological activity of drugs II: The parabolic case. J. Pharm. Sci. 1973, 62, 1-21.
26. Hestermann, E. V., J. J. Stegemann & M. E. Hahn: Relative contribution of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency. Tocixol. Appl. Pharmacol. 2000, 168, 160-172.
27. Hoare, S. A., S. Jobling, M. G. Parker, J. P. Sumpter & R. White: Environmental persistent alkylphenolic compounds are estrogenic. Endocrinology 1994, 135, 175-182.
28. Hopfinger, A. J., S. Wang, J. S. Tokarski, B. Jin, M. Albuquerque, P. J. Madhav & C. Duraiswami: Construction of 3D-QSAR models using 4D-QSAR analysis formalism. J. Amer. Chem. Soc. 1997, 119, 10509-10524.
29. Jacobs, M. N.: In silico tools to aid risk assessment of endocrinedisrupting chemicals. Toxicology 2004, 205, 43-53.
30. Kavlock, R. J., G. P. Daston, C. DeRosa, P. Fenner-Crisp, L. E. Gray, S. Kaattari, G. Lucier, M. Luster, M. J. Mac, Z. Maczka, R. Miller, J. Moore, R. Rolland, G. Scott, D. M. Sheehan, T. Sinks, & H. A. Tilson: Research needs for the risk assessment of health and environmental effects of endocrine disruptors: A report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 1996, 104, 715-740.
31. Korach, K. S., L. A. Levy & P. J. Sarver: Estrogen receptor stereochemistry: receptor binding and hormonal responses. J. Steroid Biochem. 1987, 27, 281-290.
32. Kubinyi, H.: From narcosis to hyperspace: The history of QSAR. Quant. Struct.-Act. Relat. 2002, 21, 348-356.
33. Kubinyi, H., G. Folkers & Y. C. Martin: 3D-QSAR in drug design. Volume 3. Recent advances, Kluwer/ESCOM, Dordrecht 1998; also published as Persp. Drug Disc. Design 1998b, 12-14, 1-352.
34. Kubinyi, H., G. Folkers & Y. C. Martin: 3D-QSAR in drug design. Volume 2. Ligand-protein complexes and molecular similarity, Kluwer/ESCOM, Dordrecht 1998; also published as Persp. Drug Disc. Design 1998a, 9-11, 1-416.
35. Kubinyi, H. (Ed.): 3D-QSAR in drug design. Theory, methods and applications. ESCOM Science Publishers B.V., Leiden, 1993.
36. Landers, J. P. & N. J. Bunce: The Ah receptor and the mechanism of dioxin toxicity. Biochem. J. 1991, 276, 173-287.
37. Lazar, M. A.: Thyroid hormone receptors: Multiple forms, multiple possibilities. Endocr. Rev. 1993, 14, 184-193.
38. Lewis, D. F. V., N. M. Jacobs, M. Dickins & B. G. Lake: Quantitative structure-activity inducers of cytochrome P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. Toxicology 2002, 176, 51-57.
39. Lien, E. J.: Structure-absorption-distribution relationships. In: Drug design, Volume V. Ed.: E. J. Ariëns. Academic Press, New York, 1975, pp. 81-132.
40. Lill, M. A., M. Dobler & A. Vedani: Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR. Chem. Med. Chem. 2006, 1, 73-81.
41. Lill, M. A., F. Winiger, A. Vedani & B. Ernst: Impact of induced fit on ligand binding to the androgen receptor: A multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem. 2005, 48, 5666-5674.
42. Lill, M. A., A. Vedani & M. Dobler: Raptor - combining dualshell representation, induced-fit simulation and hydrophobicity scoring in receptor modeling: Application towards the simulation of structurally diverse ligand sets. J. Med. Chem. 2004, 47, 6174-6186.
43. Lukasink, K. & A. Pitkänen: GABA(A)-mediated toxicity of hippocampal neurons in vitro. J. Neurochem. 2000, 74, 2445-2454.
44. Mazzatorta, P., E. Benfenati, C. D. Neagu & G. Gini: Tuning neural and fuzzy-neural networks for toxicity modeling. J. Chem. Inf. Comput. Sci. 2003a, 43, 513-518.
45. Mazzatorta, P., M. Vracko, A. Jezierska & E. Benfenati: Modeling toxicity by using supervised Kohonen neural networks. J. Chem. Inf. Comput. Sci. 2003b, 43, 485-492.
46. McLachlan, J. A. & S. F. Arnold: Environmental estrogens. Am. Sci. 1996, 84, 452-461.
47. Mohamadi, F., N. G. J. Richards, W. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson & W. C. Still: Macro-Model - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
48. Okey, A. B., D. S. Riddick & P. A. Harper: The Ah receptor: Mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett. 1994, 70, 1-22.
49. Oliver, J. D. & R. A. Roberts: Receptor-mediated hepatocarcinogenesis: role of hepatocyte proliferation and apoptosis. Pharmacology & Toxicology 2002, 91, 1-7.
50. Perkins, R., H. Fang, W. Tong & W. J. Welsh: Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology. Env. Tox. Chem. 2003, 8, 1666-1679.
51. Putzrath, R. M.: Estimating relative potency for receptor-mediated toxicity: Re-evaluating the toxicity equivalence factor (TEF) model. Reg. Tox. Pharmacol. 1997, 25, 68-78.
52. Rannug, U., M. Sjörgren, A. Rannug, M. Gillner, R. Toftgard, J. -Å. Gustafsson, H. Rosenkranz, & G. Klopman: Use of artificial intelligence in structure-affinity correlations of 2,3,7,8-tetrachloro-dibenzo- p-dioxin (TCDD) receptor ligands. Carcinogenesis 1991, 12, 2007- 2015.
53. Rappe, C.: Environmental concentrations and ecotoxicological effects of PCDDs, PCD Fs and related compounds. Organohalogen Compounds, Dioxin 1993, 12, 163-170.
54. Rihova, B.: Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 1998, 29, 273-289.
55. Rymer, D. L. & T. A. Good: The role of protein activation in the toxicity of amyloidogenic Aβ (1-40), Aβ (25-35), and bovine calcitonin. J. Biol. Chem. 2001, 276, 2523-2530.
56. Safe, S. & K. Krishnan: Cellular and molecular biology of Aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch. Toxicol. 1995, suppl. 17, 116-124.
57. Safe, S.: Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and related compounds: Environmental and mechanistic considerations which support the development of toxic equivalency factors (TEFs). CRC Crit. Rev. Toxicol. 1990, 21, 51-88.
58. Seidel, S. D., V. Li, G. M. Winter, W. J. Rogers, E. I. Martinez & M. S. Denison: Ah receptor based chemical screening bioassays: Application and limitations for the detection of Ah receptor antagonists. Toxicol. Sci. 2000, 55, 107-115.
59. Shi, L. M., H. Fang, W. Tong, J. Wu, R. Perkins, R. M. Blair, W. S. Branham, S. L. Dial, C. L. Moland & D. M. Sheehan: QSAR models using a large diverse set of estrogens. J. Chem. Ind. Comput. Sci. 2001, 41, 186-195.
60. Shiau, A. K., D. Barstad, P. M. Loria, L. Cheng, P. J. Kushner, D. A. Agard & G. L. Greene: The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen endogenous estrogen 17β-estradiol (E2) and the synthetic nonsteroidal estrogen diethylstilbestrol (DES). Cell 1998, 95, 927-937.
61. Swanson, H. I. & C. A. Bradfield: The Ah-Receptor: Genetics, structure and function. Pharmacogenetics 1993, 3, 213-230.
62. Swiss National Science Foundation: http://www.nrp50.ch (2001).
63. Tanaka, E.: Clinically important pharamcokinetic drug-drug interactions: Role of cytochrome P450 enzymes. J. Clin. Pharm. Therap. 1998, 23, 403-416.
64. Tong, W., W. J. Welsh, L. Shi, H. Fang & R. Perkins: Structureactivity relationship approaches and applications. Env. Tox. Chem. 2003, 22, 1680-1695.
65. Topliss, J. G. & R. J. Costello: Chance correlations in structureactivity studies using multiple regression analysis. J. Med. Chem. 1972, 15, 1066-1068.
66. Ungerer, S. H. & C. Hansch: On model building in structure-activity relationships. A reexamination of adrenergic blocking of b-halob- arlyalkylamines. J. Med. Chem. 1973, 16, 745- 749.
67. US Government: Safe Drinking Water Act Amendment. Public Law 104-182 (Section 136). See also: http://www.epa.gov.safewater/sdwa/index.html (1996a).
68. US Government: Food Quality Protection Act. Public Law 104-170 (Section 408). See also: http://www.fda.gov/opacom/laws/foodqual/fqpatoc.htm (1996b).
69. Vedani, A., M. Dobler & M. A. Lill: Virtual test kits for predicting harmful effects triggered by drugs and chemicals mediated by specific proteins. ALTEX 2005d, 22, 123-134.
70. Vedani, A., M. Dobler & M. A. Lill: In silico prediction of harmful effects triggered by drugs and chemicals. Toxicol. Appl. Pharmacol. 2005c, 207, 398-407.
71. Vedani, A., M. Dobler & M. A. Lill: Combining protein modeling and 6D-QSAR - Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005b, 48, 3700-3703.
72. Vedani, A., H. Dollinger, K.-M. Hasselbach, M. Dobler & M. A. Lill: Novel ligands for the chemokine receptor-3 (CCR3): A receptor modeling study based on 5D-QSAR. J. Med. Chem. 2005a, 48, 1515-1527.
73. Vedani, A. & M. Dobler: Internet laboratory for predicting harmful effects triggered by drugs and chemicals - A progress report. ALTEX 2003, 20, 85-91.
74. Vedani, A. & M. Dobler: 5D-QSAR: The key for simulating induced fit? J. Med. Chem. 2002, 45, 2139-2149.
75. Vedani, A. & M. Dobler: Internet laboratory for predicting harmful effects triggered by drugs and chemicals. ALTEX 2001, 18, 110-114.
76. Vedani, A., H. Briem, M. Dobler, K. Dollinger & D. R. McMasters: Multiple conformation and protonation-state representation in 4D-QSAR: The neurokinin-1 receptor system. J. Med. Chem. 2000, 43, 4416-4427.
77. Vedani, A., D. R. McMasters & M. Dobler: Genetische Algorithmen im 3D-QSAR: Verwendung multipler Wirkstofforientierugen zur verbesserten Voraussage der Toxizität. ALTEX 1999, 16, 9-14;
78. ALTEX 1999, 16, 140-143.
79. Vedani, A., M. Dobler & P. Zbinden: Quasi-atomistic receptor surface models: A bridge between 3-D QSAR and receptor modeling. J. Amer. Chem. Soc. 1998, 120, 4471-4477.
80. Vedani, A. & D. W. Huhta: An algorithm for the systematic solvation of proteins based on the directionality of hydrogen bonds. J. Amer. Chem. Soc. 1991, 113, 5860-5862.
81. Vedani, A. & D. W. Huhta: A new force field for modeling metalloproteins. J. Amer. Chem. Soc. 1990, 112, 4759-4767.
82. Waller, C. L.: A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding af-finities of structurally diverse compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 758-765.
83. Whitlock jr., J. P.: Mechanistic aspects of dioxin action. Chem. Res. Toxicol. 1993, 6, 754-763.
84. Wilson, A. G., A. C. White & R. A. Müller: Role of predictive metabolism and toxicity modeling in drug discovery - A summary of recent advancements. Curr. Opin. Drug Discov. Devel. 2003, 6, 123-128.
85. 1. J. Med. Chem. 2003, 46, 1580-1588.
86. Zubay, G. L., W. W. Parson & D. E. Vance: Principles of biochemistry. Wm. C. Brown Communications, Inc., Dubuque, USA, 1995.
87. Zumstein, M.: Establishing a quantitative structure-activity relationship for the α/β selectivity of the thyroid receptor. M. Sc. thesis, Department of Pharmacy, University of Basel, 2005.